Sotac Pharmaceuticals

Sotac Pharmaceuticals Assets per Share

The Total Assets per Share of Sotac Pharmaceuticals (SOTAC.NS) as of Oct 21, 2026 is 112.51 INR. In the previous year, Total Assets per Share was 95.29 INR — a change of 18.07% (higher).

Assets per Share

112.51INR

YoY

18.07%

Last updated:

Total Assets per Share of Sotac Pharmaceuticals is 2025 112.51 INR. Total Assets per Share of Sotac Pharmaceuticals was 2024 95.29 INR. It decreases by 18.07% higher compared to the previous year.

The Sotac Pharmaceuticals Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2020
27.50 INR
Jan 1, 2021
31.40 INR
Jan 1, 2022
31.90 INR
Jan 1, 2024
95.29 INR
Jan 1, 2025
112.51 INR
The Sotac Pharmaceuticals Assets per Share history
YEARAssets per ShareYoY
112.51INR+18.07%
95.29INR+198.69%
31.90INR+1.60%
31.40INR+14.20%
27.50INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sotac Pharmaceuticals Stock analysis

What does Sotac Pharmaceuticals do? Sotac Pharmaceuticals Ltd develops and manufactures pharmaceutical products under loan license or contract manufacturing agreements for various marketers. The company specializes in Non Beta-Lactam tablets, capsules, syrup, and external preparations, with a therapeutic portfolio covering Anti-Diabetic, Anti-Psychotic, Vitamins, Minerals, Iron, Anti-Cold, Anti-Allergic, Derma Products, Antacid, Anti-Ulcerants, PPI, Anti-Emetics, Cardiac, Anti-Hypertensives, Analgesic, Anti-Pyretic, Anti-Inflammatory, Anti-Bacterial, Anti-Viral, General Antibiotics IP-Lactams and Non-IP-Lactams, Anti-Fungal, and Cephalosporin products. Its subsidiaries SOTAC Healthcare, SOTAC Research, and SOTAC Lifescience support its manufacturing and development activities. The company generates revenue by producing pharmaceutical products on a contract manufacturing basis for different marketers, who then market and sell these products under their own brands. Sotac Pharmaceuticals' manufacturing services are utilized by various marketers seeking to outsource production without maintaining their own facilities. The firm's focus on a diverse therapeutic portfolio ensures consistent demand across multiple healthcare segments. Sotac Pharmaceuticals' manufacturing capabilities are tailored to meet the specific requirements of its marketer clients, offering both Non Beta-Lactam and Beta-Lactam product lines. The company's subsidiaries provide additional support in healthcare, research, and lifescience sectors, enhancing its overall service offerings. Its product range spans from basic medications like Anti-Cold and Anti-Allergic to specialized treatments such as Anti-Fungal and Cephalosporin antibiotics. Sotac Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sotac Pharmaceuticals stock

Total Assets per Share of Sotac Pharmaceuticals is 112.51 INR in 2025.

Total Assets per Share of Sotac Pharmaceuticals changed from 95.29 INR to 112.51 INR, representing a 18.07% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Sotac Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Sotac Pharmaceuticals

All Key Metrics — Sotac Pharmaceuticals